Omnicell (NASDAQ:OMCL) reported robust financial results for the first quarter of 2026, highlighted by a return to GAAP profitability and significant top-line acceleration.
The California-based healthcare technology provider posted total revenues of $310 million, a 15% increase compared to the $270 million reported in the first quarter of 2025.
The revenue jump was driven by broad-based strength across the company’s portfolio, specifically within its connected devices segment.
Omnicell also realized significant gains in technical services, consumables, and its high-margin SaaS and Expert Services offerings.
This shift toward service-based and digital solutions continues to be a cornerstone of the firm's strategy to automate the medication management process for health systems.
Profitability metrics showed a marked turnaround from the prior-year period.
Omnicell reported GAAP net income of $11 million, or $0.25 per diluted share, compared to a net loss of $7 million in the first quarter of 2025.
On an adjusted basis, the improvement was even more pronounced; total non-GAAP net income reached $25 million ($0.55 per diluted share), more than doubling the $12 million recorded a year ago.
Non-GAAP EBITDA also saw a steep climb, rising to $45 million from $24 million.
Omnicell’s balance sheet remains solid, ending the quarter with $239 million in cash and cash equivalents against a total debt of $168 million.
Cash flows provided by operating activities totaled $55 million for the quarter, a significant increase from the $26 million generated in the same period last year.
With $2 billion in total assets and a strengthening cash position, the company is well-positioned to continue investing in its AI-driven medication management platform as hospitals seek deeper automation to drive safety and efficiency.